Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]-Exicorilant in Healthy Subjects
NCT03877952Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exicorilant in castration-resistant prostate cancer (CRPC), sponsored by Corcept Therapeutics. Primary endpoint: Mass Balance Recovery in Excreta After a Single Oral Dose of 14C-CORT125281 up to 10 days. Started Sep 2018; status: completed.
02
Drugs
exicorilant
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03877952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877952.